Platelet count as a screening tool for compensated cirrhosis in chronic viral hepatitis
World Journal of Gastrointestinal Pathophysiology · 22.05.2021 · 12 (3) · 40-50
DOI: 10.4291/wjgp.v12.i3.40 ↗Kurz gefasst
Fachartikel in der Zeitschrift World Journal of Gastrointestinal Pathophysiology, erschienen am 22.05.2021. Verfasst von Pallavi Surana und 5 weiteren Autor:innen. Beteiligte Einrichtung: Liver Diseases Branch, National Institute of Diabetes and Digestive and Kidney Diseases, Bethesda, MD 20892, United States. Die Arbeit wurde bisher 12-mal zitiert (Crossref) und nennt 37 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar.
Abstract (Originalsprache)
BACKGROUND: Simple tools for clinicians to identify cirrhosis in patients with chronic viral hepatitis are medically necessary for treatment initiation, hepatocellular cancer screening and additional medical management. AIM: To determine whether platelets or other laboratory markers can be used as a simple method to identify the development of cirrhosis. METHODS: Clinical, biochemical and histologic laboratory data from treatment naive chronic viral hepatitis B (HBV), C (HCV), and D (HDV) patients at the NIH Clinical Center from 1985-2019 were collected and subjects were randomly divided into training and validation cohorts. Laboratory markers were tested for their ability to identify cirrhosis (Ishak ≥ 5) using receiver operating characteristic curves and an optimal cut-off was calculated within the training cohort. The final cut-off was tested within the validation cohort. RESULTS: Overall, 1027 subjects (HCV = 701, HBV = 240 and HDV = 86), 66% male, with mean (standard deviation) age of 45 (11) years were evaluated. Within the training cohort (n = 715), platelets performed the best at identifying cirrhosis compared to other laboratory markers [Area Under the Receiver Operating Characteristics curve (AUROC) = 0.86 (0.82-0.90)] and sensitivity 77%, specificity 83%, positive predictive value 44%, and negative predictive value 95%. All other tested markers had AUROCs ≤ 0.77. The optimal platelet cut-off for detecting cirrhosis in the training cohort was 143 × 109/L and it performed equally well in the validation cohort (n = 312) [AUROC = 0.85 (0.76-0.94)]. CONCLUSION: The use of platelet counts should be considered to identify cirrhosis and ensure optimal care and management of patients with chronic viral hepatitis.
Schlagwörter
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Liver Diseases Branch, National Institute of Diabetes and Digestive and Kidney Diseases, Bethesda, MD 20892, United States.
- Laboratory of Pathology, National Cancer Institute, Bethesda, MD 20892, United States.
- Liver Diseases Branch, National Institute of Diabetes and Digestive and Kidney Diseases, Bethesda, MD 20892, United States. christopher.koh@nih.gov.
Zitieren
APA
Surana, P., Hercun, J., Takyar, V., Kleiner, D. E., Heller, T., & Koh, C. (2021). Platelet count as a screening tool for compensated cirrhosis in chronic viral hepatitis. World Journal of Gastrointestinal Pathophysiology, 12(3), 40-50. https://doi.org/10.4291/wjgp.v12.i3.40
Vancouver
Surana P, Hercun J, Takyar V, Kleiner DE, Heller T, Koh C. Platelet count as a screening tool for compensated cirrhosis in chronic viral hepatitis. World Journal of Gastrointestinal Pathophysiology. 2021;12(3):40-50. doi:10.4291/wjgp.v12.i3.40
BibTeX
@article{Surana2021,
author = {Surana, Pallavi and Hercun, Julian and Takyar, Varun and Kleiner, David E and Heller, Theo and Koh, Christopher},
title = {Platelet count as a screening tool for compensated cirrhosis in chronic viral hepatitis},
journal = {World Journal of Gastrointestinal Pathophysiology},
year = {2021},
volume = {12},
number = {3},
pages = {40--50},
doi = {10.4291/wjgp.v12.i3.40}
}
EUVIMED